Opinion

Video

Duration of PARP Inhibitor Maintenance Therapy for Ovarian Cancer

Author(s):

Angeles Alvarez Secord, MD, MHSc Dana M. Chase, MD, FACOG

Panelists explore emerging combination therapies in maintenance treatment for advanced ovarian cancer, including rucaparib + nivolumab; atezolizumab + bevacizumab; and olaparib + cediranib, also discussing how these strategies fit into the current treatment paradigm and in which patient populations they may be considered.

Video content above is prompted by the following:

  • Typically, how long do you keep patients on PARP inhibitors in first-line maintenance? What about second-line maintenance? 
Related Videos
5 KOLs are featured in this series.
Hope Rugo, MD, FASCO, and Aditya Bardia, MD, MPH, FASCO
2 KOLs are featured in this series.
2 KOLs are featured in this series.
5 KOLs are featured in this series.
5 KOLs are featured in this series.
Related Content
Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment
September 15th 2021

Advanced Systemic Mastocytosis: Expert Insight into Epidemiology, Diagnosis, and Treatment